167 related articles for article (PubMed ID: 15599851)
1. The epidermal growth factor receptor signaling network in head and neck carcinogenesis and implications for targeted therapy.
Pomerantz RG; Grandis JR
Semin Oncol; 2004 Dec; 31(6):734-43. PubMed ID: 15599851
[TBL] [Abstract][Full Text] [Related]
2. Targeting EGF-receptor-signalling in squamous cell carcinomas of the head and neck.
Reuter CW; Morgan MA; Eckardt A
Br J Cancer; 2007 Feb; 96(3):408-16. PubMed ID: 17224925
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of epidermal growth factor receptor gene expression and function decreases proliferation of head and neck squamous carcinoma but not normal mucosal epithelial cells.
Rubin Grandis J; Chakraborty A; Melhem MF; Zeng Q; Tweardy DJ
Oncogene; 1997 Jul; 15(4):409-16. PubMed ID: 9242377
[TBL] [Abstract][Full Text] [Related]
4. Overview of Current Treatment Options and Investigational Targeted Therapies for Locally Advanced Squamous Cell Carcinoma of the Head and Neck.
Zibelman M; Mehra R
Am J Clin Oncol; 2016 Aug; 39(4):396-406. PubMed ID: 26967327
[TBL] [Abstract][Full Text] [Related]
5. Epidermal growth factor receptor (EGFR) and squamous cell carcinoma of the skin: molecular bases for EGFR-targeted therapy.
Uribe P; Gonzalez S
Pathol Res Pract; 2011 Jun; 207(6):337-42. PubMed ID: 21531084
[TBL] [Abstract][Full Text] [Related]
6. The role of cetuximab in the treatment of squamous cell cancer of the head and neck.
Burtness B
Expert Opin Biol Ther; 2005 Aug; 5(8):1085-93. PubMed ID: 16050785
[TBL] [Abstract][Full Text] [Related]
7. Targeting pathways mediating resistance to anti-EGFR therapy in squamous cell carcinoma of the head and neck.
Campbell NP; Hensing TA; Bhayani MK; Shaikh AY; Brockstein BE
Expert Rev Anticancer Ther; 2016 Aug; 16(8):847-58. PubMed ID: 27400139
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of human squamous cell carcinoma growth in vivo by epidermal growth factor receptor antisense RNA transcribed from the U6 promoter.
He Y; Zeng Q; Drenning SD; Melhem MF; Tweardy DJ; Huang L; Grandis JR
J Natl Cancer Inst; 1998 Jul; 90(14):1080-7. PubMed ID: 9672256
[TBL] [Abstract][Full Text] [Related]
9. EGFR-targeted therapies in the post-genomic era.
Xu MJ; Johnson DE; Grandis JR
Cancer Metastasis Rev; 2017 Sep; 36(3):463-473. PubMed ID: 28866730
[TBL] [Abstract][Full Text] [Related]
10. Epidermal growth factor receptor directed therapy in head and neck cancer.
Choong NW; Cohen EE
Crit Rev Oncol Hematol; 2006 Jan; 57(1):25-43. PubMed ID: 16207530
[TBL] [Abstract][Full Text] [Related]
11. Targeting growth factor receptors: integration of novel therapeutics in the management of head and neck cancer.
Lango MN; Shin DM; Grandis JR
Curr Opin Oncol; 2001 May; 13(3):168-75. PubMed ID: 11307060
[TBL] [Abstract][Full Text] [Related]
12. Simultaneous β1 integrin-EGFR targeting and radiosensitization of human head and neck cancer.
Eke I; Zscheppang K; Dickreuter E; Hickmann L; Mazzeo E; Unger K; Krause M; Cordes N
J Natl Cancer Inst; 2015 Feb; 107(2):. PubMed ID: 25663685
[TBL] [Abstract][Full Text] [Related]
13. Biology and patterns of response to EGFR-inhibition in squamous cell cancers of the lung and head & neck.
Juergens RA; Bratman SV; Tsao MS; Laurie SA; Sara Kuruvilla M; Razak AR; Hansen AR
Cancer Treat Rev; 2017 Mar; 54():43-57. PubMed ID: 28192747
[TBL] [Abstract][Full Text] [Related]
14. Antitumor effects of epidermal growth factor receptor antisense oligonucleotides in combination with docetaxel in squamous cell carcinoma of the head and neck.
Niwa H; Wentzel AL; Li M; Gooding WE; Lui VW; Grandis JR
Clin Cancer Res; 2003 Oct; 9(13):5028-35. PubMed ID: 14581378
[TBL] [Abstract][Full Text] [Related]
15. Antitumor mechanisms of systemically administered epidermal growth factor receptor antisense oligonucleotides in combination with docetaxel in squamous cell carcinoma of the head and neck.
Thomas SM; Ogagan MJ; Freilino ML; Strychor S; Walsh DR; Gooding WE; Grandis JR; Zamboni WC
Mol Pharmacol; 2008 Mar; 73(3):627-38. PubMed ID: 18025070
[TBL] [Abstract][Full Text] [Related]
16. The epidermal growth factor receptor (EGFR) in head and neck cancer: its role and treatment implications.
Zimmermann M; Zouhair A; Azria D; Ozsahin M
Radiat Oncol; 2006 May; 1():11. PubMed ID: 16722544
[TBL] [Abstract][Full Text] [Related]
17. Intratumoral epidermal growth factor receptor antisense DNA therapy in head and neck cancer: first human application and potential antitumor mechanisms.
Lai SY; Koppikar P; Thomas SM; Childs EE; Egloff AM; Seethala RR; Branstetter BF; Gooding WE; Muthukrishnan A; Mountz JM; Lui VW; Shin DM; Agarwala SS; Johnson R; Couture LA; Myers EN; Johnson JT; Mills G; Argiris A; Grandis JR
J Clin Oncol; 2009 Mar; 27(8):1235-42. PubMed ID: 19204206
[TBL] [Abstract][Full Text] [Related]
18. Treatment of squamous cell carcinoma of the head and neck in the metastatic and refractory settings: advances in chemotherapy and the emergence of small molecule epidermal growth factor receptor kinase inhibitors.
Ahmed SM; Cohen EE
Curr Cancer Drug Targets; 2007 Nov; 7(7):666-73. PubMed ID: 18045071
[TBL] [Abstract][Full Text] [Related]
19. Current challenges and clinical investigations of epidermal growth factor receptor (EGFR)- and ErbB family-targeted agents in the treatment of head and neck squamous cell carcinoma (HNSCC).
Cohen RB
Cancer Treat Rev; 2014 May; 40(4):567-77. PubMed ID: 24216225
[TBL] [Abstract][Full Text] [Related]
20. Mechanisms of and therapeutic approaches for overcoming resistance to epidermal growth factor receptor (EGFR)-targeted therapy in squamous cell carcinoma of the head and neck (SCCHN).
Price KA; Cohen EE
Oral Oncol; 2015 May; 51(5):399-408. PubMed ID: 25725588
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]